Hims & Hers Health, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hims & Hers Health, Inc. operates a telehealth platform providing direct-to-consumer healthcare services and products primarily across the United States, the United Kingdom, and select European markets, with plans for further global expansion. The company offers a comprehensive range of core products and services including prescription medications, over-the-counter drugs, and personal care products under its consumer-facing brands Hims (targeting men) and Hers (targeting women). Key product categories encompass sexual health treatments such as erectile dysfunction medications and birth control; hair care products including hair loss treatments; mental health services including therapy and coaching; weight loss programs integrating medication; skincare products; and preventive health solutions. The platform connects customers with licensed healthcare providers who deliver personalized treatment plans through virtual consultations, often asynchronously, supported by ongoing clinical care and educational resources. Hims & Hers also operates vertically integrated pharmacy fulfillment facilities alongside partnerships with external pharmacies for prescription delivery. Founded in 2017 and headquartered in San Francisco, California, Hims & Hers has rapidly evolved from focusing initially on men's health and stigmatized conditions like erectile dysfunction to a broad telehealth ecosystem covering multiple specialties and wellness areas for both men and women. Recent major developments include the acquisition of YourBio Health, which brings advanced pain-free blood sampling technology to enhance diagnostic services, and the strategic acquisition of ZAVA, a leading European digital health platform, which expands Hims & Hers’ footprint into the UK, Germany, France, and Ireland with plans to further penetrate European markets. The company also announced a significant collaboration with Novo Nordisk to expand affordable access to obesity care, alongside launching AI-powered tools like MedMatch to personalize treatment plans using large-scale data analytics. Additionally, Hims & Hers initiated a $250 million share repurchase program in 2025 and planned a market entry into Canada timed with availability of generic weight loss medication semaglutide. Hims & Hers operates within the broader healthcare and biotechnology sectors and targets adult consumers seeking accessible, affordable, and stigma-free telehealth services and products. Its business model integrates telemedicine consultations, electronic medical records, cloud-based pharmacy fulfillment, and personalized healthcare technology. With over 2.4 million subscribers as of mid-2025, the company has scaled its operations nation-wide in the US and strategically expanded internationally through acquisitions and partnerships with major health systems like Ochsner, Mount Sinai, and Hartford Healthcare to enhance continuity of care that bridges digital and in-person services. The firm's continuous innovation and targeted market expansion position it as a growing leader in global digital health and wellness delivery.
Kaplan Fox & Kilsheimer LLP Announces an Investigation into Hims & Hers Health, Inc. (HIMS) for Possible Securities Law Violations
Hims & Hers Health's Next Act: Making Its Own Drugs Again
HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation
HIMS SHAREHOLDER ALERT: Hims & Hers Health, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
As Hims prepares for peptides launch, Wall Street cautious on prospects this year
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (HIMS) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS)
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS)
Hims & Hers: The Guidance Raise Doesn't Fix The Margin Problem
FTC Continues Investigation into Hims & Hers Health, Inc. as Lowey Dannenberg Files Class Action Complaint on Behalf of Consumers
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down
Hims & Hers Q2 revenue beat offset by wider-than-expected loss
Hims & Hers Health (HIMS) Faces Profitability Concerns Amid Strong Revenue Growth
HIMS Q2 Earnings Call Focuses on AI and Global Expansion
Tuesday's Morning Movers: RKLB & HIMS Earnings, RIOT Gets Anthropic Deal
Kaplan Fox Alerts Hims & Hers Health, Inc. (HIMS) Investors to an Investigation of Potential Securities Law Violations